Mirum Pharmaceuticals stock snapshot after recent performance shifts

Mirum Pharmaceuticals (MIRM) has had mixed share-price moves recently, with a small 1 day gain, a 12% decline over the past week, a 10% drop over the past month, and a 32% gain across the past 3 months.

Against that backdrop, investors are weighing Mirum’s current US$92.29 share price, its recent return profile over the past year and beyond, and how that lines up with the company’s rare disease portfolio and financial results.

Recent trading has been choppy, with short term share price pressure contrasted by stronger longer term total shareholder returns. This suggests that sentiment around Mirum’s rare disease portfolio and risk profile has been shifting rather than moving in a straight line.

If Mirum’s moves have you thinking about where else growth stories might emerge in healthcare, it could be worth scanning our list of 27 healthcare AI stocks as a starting point for ideas.

With Mirum posting a 94% 1 year total return, rapid revenue and net income growth, and trading at US$92.29 versus an average analyst target of US$122.36, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 13.4% Undervalued

Against Mirum Pharmaceuticals' last close at $92.29, the most followed narrative points to a fair value of $106.60, anchored on detailed revenue and margin assumptions and a 7.17% discount rate.

The analysts have a consensus price target of $78.273 for Mirum Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $89.0, and the most bearish reporting a price target of just $53.0.

Want to see what sits behind that fair value gap? The narrative leans on brisk revenue expansion, a swing to profitability, and a rich future earnings multiple. Curious how those pieces fit together and what assumptions really drive $106.60?

Result: Fair Value of $106.60 (UNDERVALUED)

However, the current narrative still leans heavily on Livmarli and assumes smooth late stage trial execution, and any clinical setbacks or reimbursement pushback could quickly challenge that view.

Another view: pricing against sales multiples

The SWS DCF model points to a large gap between price and fair value, but the simple P/S check is more restrained. Mirum trades on a 10.7x P/S, above its 9.7x fair ratio, yet below both peer (12.7x) and wider US biotech averages (12.4x). Is that a margin of safety or a value trap forming?

Next Steps

If this mix of optimism and caution feels familiar, now is a good time to look through the numbers yourself and decide where you stand. This includes 4 key rewards and 2 important warning signs.

Ready for more investment ideas?

If Mirum has sharpened your thinking, do not stop there. Use the Simply Wall St screener to hunt for clear, data driven opportunities that suit your style.

• Target value potential by scanning our list of 46 high quality undervalued stocks that currently pair quality fundamentals with prices that may not fully reflect them.
• Prioritise staying power by checking the solid balance sheet and fundamentals stocks screener (39 results) that focus on companies with financial structures designed to handle pressure.
• Spot off the radar opportunities through the screener containing 24 high quality undiscovered gems that highlight quality businesses less crowded by attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.